Furthermore, the discernible involvement of EVI2A in the immune microenvironment of renal cell carcinoma unveils novel perspectives that could significantly impact the landscape of immunotherapeutic approaches for this disease. This evidence concerns the gene EVI2A and hereditary clear cell renal cell carcinoma.